July 8, 2020, 2:24 a.m. EDT

AstraZeneca gets EU OK for pancreatic cancer drug

By Sabela Ojea

AstraZeneca PLC said Wednesday that its Lynparza medicine has been approved in the European Union for patients diagnosed with germline BRCA-mutated metastatic pancreatic cancer, one of the most common cancers with the lowest survival rate.

The pharmaceutical giant said the approval was based on results from the Phase 3 Polo trial.

Only around 5% to 7% of these patients with metastatic pancreatic cancer have a germline BRCA mutation, the London-listed company said.

"Lynparza is approved in the U.S. and several other countries as a 1st-line maintenance treatment for patients with gBRCAm metastatic pancreatic cancer based on the Phase 3 Polo trial , with ongoing regulatory reviews in other regions," AstraZeneca said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

Link to MarketWatch's Slice.